Background We assessed the efficacy and safety of programmed cell death 1 (PD-1)
inhibition with pembrolizumab in patients with advanced non–small-cell lung cancer …

Background The anti-programmed death 1 monoclonal antibody pembrolizumab has shown
antitumour activity and is a first-line and second-line treatment option for patients with …

Background Pembrolizumab is a humanized monoclonal antibody against programmed
death 1 (PD-1) that has antitumor activity in advanced non–small-cell lung cancer (NSCLC) …

PURPOSE Pembrolizumab monotherapy has demonstrated durable antitumor activity in
advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer …

Background Pembrolizumab improved survival as first-and second-line therapy compared
with chemotherapy in patients with highly programmed death ligand 1 (PD-L1) expressing …

Background In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1)
expression on≥ 50% of tumor cells, first-line treatment with the PD-1 inhibitor …

Background Pembrolizumab plus platinum‐based chemotherapy has demonstrated
improved clinical outcomes over chemotherapy alone in patients with previously untreated …

Introduction: Immune checkpoint inhibitors targeting programmed death protein 1 (PD-1)
receptor and its ligand, PD-L1, have recently led to significant and durable improvements in …

To the Editor: In the KEYNOTE-189 trial, Gandhi et al.(May 31 issue) 1 compared
pembrolizumab plus chemotherapy with chemotherapy alone in patients with untreated …

Pembrolizumab monotherapy has become the preferred treatment for patients with
advanced non-small cell lung carcinoma (NSCLC) and a programmed cell death-ligand 1 …